share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰制药 | 144:拟议出售证券
美股SEC公告 ·  08/30 16:48

Moomoo AI 已提取核心信息

Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 646 shares of common stock on 08/30/2024, with an aggregate market value of approximately $323,000. The shares were acquired on the same date through an option granted on 06/01/2018, and will be paid for in cash. This transaction follows a previous sale of 1,292 shares in the past three months, which had gross proceeds of $602,446.68. The planned sale is part of a trading plan adopted on 05/09/2024.
Vertex Pharmaceuticals Inc. Director Sangeeta N. Bhatia is set to sell 646 shares of common stock on 08/30/2024, with an aggregate market value of approximately $323,000. The shares were acquired on the same date through an option granted on 06/01/2018, and will be paid for in cash. This transaction follows a previous sale of 1,292 shares in the past three months, which had gross proceeds of $602,446.68. The planned sale is part of a trading plan adopted on 05/09/2024.
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia计划于08/30/2024出售646股普通股,估计市值约为323,000美元。这些股份是在06/01/2018通过授予的期权获得的,将以现金支付。此次交易是过去三个月内出售的1,292股股份的继续,总收益为602,446.68美元。计划的销售是在05/09/2024采取的交易计划的一部分。
Vertex Pharmaceuticals Inc.董事Sangeeta N. Bhatia计划于08/30/2024出售646股普通股,估计市值约为323,000美元。这些股份是在06/01/2018通过授予的期权获得的,将以现金支付。此次交易是过去三个月内出售的1,292股股份的继续,总收益为602,446.68美元。计划的销售是在05/09/2024采取的交易计划的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息